MedTrace Logo

Maraviroc Intensification and Peripheral Blood Monocyte HIV DNA Levels

NCT00987948 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2017-03-22

Study results available
· View outcomes & findings →

Summary

High levels of HIV infection within blood monocyte/macrophages (a type of white cells in the bloodstream) increases risk of dementia in HIV-infected individuals. Maraviroc (Selzentry) is a HIV medication that works by blocking the entry of HIV in cells including monocytes/macrophages that use a receptor called CCR5. The study hypothesis is that the addition of Maraviroc to a HIV antiretroviral regimen in HIV-infected individuals with high levels of HIV-infected monocyte/macrophages will lead to a decrease in the levels of infected monocyte/macrophages and to decrease in brain inflammation as studied by magnetic resonance spectroscopy (MRS, a form of MRI study).

Conditions

  • HIV Infections

Interventions

DRUG

maraviroc (Selzentry)

dosage varies with other medications being taken; will follow package insert guidelines

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • University of Hawaii

    lead OTHER

Principal Investigators

  • Cecilia M Shikuma, M.D. · University of Hawaii at Manoa

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-11-30
Completion
2013-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00987948 on ClinicalTrials.gov